Tazobactum%252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a combination extended-spectrum penicillin antibiotic paired with a beta-lactamase inhibitor. It provides coverage against Gram-positive, Gram-negative (including *Pseudomonas aeruginosa*), and anaerobic organisms. ## Primary Indications * Severe pneumonia (community or hospital-acquired). * Intra-abdominal infections (e.g., appendicitis, peritonitis). * Skin and skin structure infections. * Gynecologic infections (e.g., postpartum endometritis, PID). * Febrile neutropenia (empiric therapy). ## Adult Dosing * **Standard dosing:** 3.375 g (3 g piperacillin / 0.375 g tazobactam) IV every 6 hours. * **Severe infections:** 4.5 g (4 g piperacillin / 0.5 g tazobactam) IV every 6 or 8 hours. * **Maximum dose:** 18 g piperacillin content per 24 hours. * **Administration:** Typically infused over 4 hours (extended infusion) in critically ill patients to optimize pharmacodynamics. ## Pediatric Dosing * **Neonates (0–9 days):** 80 mg/kg/dose (piperacillin component) every 12 hours. * **Neonates (10+ days) and infants:** 80 mg/kg/dose every 8 hours. * **Children (aged 2–9 months):** 80 mg/kg/dose every 8 hours. * **Children (≥9 months to 12 years):** 100 mg/kg/dose every 8 hours (maximum 4 g piperacillin per dose). * *Note: Always verify with local pediatric protocols or institutional formulary guidelines.* ## Dose Adjustments * **Renal Impairment:** Requires dose reduction if CrCl ≤ 40 mL/min. * CrCl 20–40 mL/min: 2.25 g every 8 hours. * CrCl < 20 mL/min: 2.25 g every 12 hours. * **Hemodialysis:** Supplementation is required; maintenance dose should not exceed 2.25 g every 12 hours, plus a 0.75 g post-dialysis dose. ## Contraindications * History of severe hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to piperacillin, tazobactam, or any beta-lactam antibiotic. ## Adverse Effects * **Common:** Diarrhea, constipation, nausea, headache, injection site reaction. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), neutropenia (with prolonged use), anaphylaxis, rash, and electrolyte disturbances (hypernatremia from high sodium content in infusions). ## Key Drug Interactions * **Aminoglycosides:** Inactivation of aminoglycosides if mixed in the same IV line. Administer at least 1 hour apart. * **Probenecid:** Increases piperacillin serum concentrations by delaying renal excretion. * **Warfarin:** Theoretical risk of increased bleeding due to alteration of gut flora or potential platelet dysfunction at high doses. * **Methotrexate:** Penicillins may decrease renal clearance, increasing methotrexate toxicity. ## Monitoring * **Renal function:** CrCl at baseline and periodically during therapy. * **Hematology:** CBC with differential (monitor for leukopenia/neutropenia if therapy exceeds 10–14 days). * **Clinical response:** Resolution of fever, leukocytosis, and infection-specific symptoms. ## Clinical Pearls * **Sodium content:** Each 4.5 g dose contains approximately 1.12 mmol (approx 280 mg) of sodium; use caution in patients on restricted sodium diets or with heart failure. * **Extended Infusion:** Prolonging the infusion time (e.g., 4 hours) maintains antibiotic concentrations above the MIC for a greater percentage of the dosing interval, which is often preferred for *Pseudomonas* or critically ill patients. * **Beta-lactam allergy:** Always ascertain the nature of a reported "penicillin allergy" before prescribing, as mild reactions may not contraindicate standard use depending on institutional policy. *** **Educational Disclaimer:** This information is for educational purposes only. Always verify doses, contraindications, and drug interactions against the most current institutional protocols and the official product prescribing information (package insert) before finalizing a prescription.